MedTrace Logo

Phase 2 Study in Adults Sensitized to Short Ragweed

NCT00670384 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-01-09

No results posted yet for this study

Summary

The purpose of this study is to identify an effective dose of allergen-specific immunotherapy for short ragweed (Ambrosia artemisiifolia) administered by an oral/sublingual route.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)

Sublingual drops

BIOLOGICAL

Placebo

Sublingual drops

Sponsors & Collaborators

  • Antigen Laboratories, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670384 on ClinicalTrials.gov